Key result
Patients with congestive heart failure had significantly higher levels of TACE and TNF-alpha mRNAs and proteins in peripheral blood mononuclear cells compared to controls (P<0.001).
Why the study?
Are TACE and TNF-alpha levels increased in PBMC of patients with congestive heart failure compared to controls?
Population
46 patients with congestive heart failure (CHF) and 22 controls
Design
Case-control
Authors
Loading...
TACE may be a novel CHF treatment target; hypothesis-generating and requires outcome trials before clinical consideration.
Case-Control (n=68)
Are TACE and TNF-alpha levels increased in PBMC of patients with congestive heart failure compared to controls?
p-value: p=<0.001
TACE expression is increased alongside TNF-alpha in PBMCs of patients with CHF, correlating with disease severity and highlighting TACE as a potential therapeutic target.
Satoh et al. (2004) conducted a case-control in Congestive heart failure (n=68). Congestive heart failure vs. Controls was evaluated on Levels of TACE and TNF-alpha mRNAs, intracellular TACE and TNF-alpha, and supernatant TNF-alpha (p=<0.001). Patients with congestive heart failure had significantly higher levels of TACE and TNF-alpha mRNAs and proteins in peripheral blood mononuclear cells compared to controls (P<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: